Abstract
Adjuvant systemic therapy for cutaneous melanoma has experienced practice-changing shifts over the last decade. The successful results of immunotherapies and targeted therapies in the metastatic setting have allowed for investigative trials of the same therapies in the adjuvant and now neoadjuvant setting, with the potential for improved clinical outcomes in patients with high risk resected Stage III and IV melanoma.
Keywords:
BRAF; PD-1; clinical trials; immunotherapy.
© 2021 Wiley Periodicals LLC.
MeSH terms
-
Chemotherapy, Adjuvant
-
Clinical Trials, Phase III as Topic
-
Humans
-
Immune Checkpoint Inhibitors / administration & dosage
-
Melanoma / drug therapy*
-
Melanoma / pathology
-
Melanoma / surgery*
-
Melanoma, Cutaneous Malignant
-
Neoadjuvant Therapy
-
Neoplasm Staging
-
Protein Kinase Inhibitors / administration & dosage
-
Randomized Controlled Trials as Topic / methods*
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / pathology
-
Skin Neoplasms / surgery*
Substances
-
Immune Checkpoint Inhibitors
-
Protein Kinase Inhibitors